These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

867 related items for PubMed ID: 28276638

  • 1. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL.
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [Abstract] [Full Text] [Related]

  • 2. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 3. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ.
    N Engl J Med; 2002 Feb 28; 346(9):653-61. PubMed ID: 11870242
    [Abstract] [Full Text] [Related]

  • 4. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 28; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 5. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.
    McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL.
    Obstet Gynecol; 2009 Nov 28; 114(5):999-1007. PubMed ID: 20168099
    [Abstract] [Full Text] [Related]

  • 6. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar 28; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
    Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, Sone T, Taguchi A, Tanaka S, Ohashi M, Ota Y, Shiraki M.
    Osteoporos Int; 2017 Jan 28; 28(1):389-398. PubMed ID: 27631091
    [Abstract] [Full Text] [Related]

  • 8. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial.
    N Engl J Med; 2007 May 03; 356(18):1809-22. PubMed ID: 17476007
    [Abstract] [Full Text] [Related]

  • 9. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
    Koldkjær Sølling AS, Harsløf T, Langdahl B.
    Osteoporos Int; 2019 May 03; 30(5):995-1002. PubMed ID: 30656367
    [Abstract] [Full Text] [Related]

  • 10. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct 03; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 11. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
    Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R.
    J Bone Miner Res; 2012 Aug 03; 27(8):1627-34. PubMed ID: 22532515
    [Abstract] [Full Text] [Related]

  • 12. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.
    Osteoporos Int; 2014 Jul 03; 25(7):1953-61. PubMed ID: 24676847
    [Abstract] [Full Text] [Related]

  • 13. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P, Kauka A, Ziller M, Birkholz K, Baier M, Muth M, Bauer M.
    Osteoporos Int; 2014 Apr 03; 25(4):1369-78. PubMed ID: 24504100
    [Abstract] [Full Text] [Related]

  • 14. Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion.
    Chen F, Dai Z, Kang Y, Lv G, Keller ET, Jiang Y.
    Osteoporos Int; 2016 Apr 03; 27(4):1469-1476. PubMed ID: 26556733
    [Abstract] [Full Text] [Related]

  • 15. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
    Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM, HORIZON Pivotal Fracture Trial.
    Osteoporos Int; 2010 Jul 03; 21(7):1277-85. PubMed ID: 19802508
    [Abstract] [Full Text] [Related]

  • 16. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
    Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW.
    Ann Intern Med; 2006 Feb 21; 144(4):239-48. PubMed ID: 16490909
    [Abstract] [Full Text] [Related]

  • 17. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G, Kriegman A, Gonçalves J, Kianifard F, Warren M, Simon JA.
    Menopause; 2011 Aug 21; 18(8):851-6. PubMed ID: 21796066
    [Abstract] [Full Text] [Related]

  • 18. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.
    J Clin Oncol; 2007 Mar 20; 25(9):1038-42. PubMed ID: 17369566
    [Abstract] [Full Text] [Related]

  • 19. Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.
    Bubbear JS, Gall A, Middleton FR, Ferguson-Pell M, Swaminathan R, Keen RW.
    Osteoporos Int; 2011 Jan 20; 22(1):271-9. PubMed ID: 20358358
    [Abstract] [Full Text] [Related]

  • 20. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Osteoporos Int; 2015 Oct 20; 26(10):2521-7. PubMed ID: 25990355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.